Personalised Medicine: Navigating Drug-Diagnostic Co-development

The anticipated success of personalised medicine depends largely on a molecular-targeted drug having a linked, or ‘companion’, diagnostic test designed to determine precisely whether a patient will benefit from the specific treatment. Click here to read the full version of the article written by Brandwood Biomedical senior consultant Paul Cohen, published in the April edition of the Australasian Biotechnology e-journal, about the regulatory challenges of obtaining coordinated approval for both drug and diagnostic.